Quality assurance within the scope of Good Clinical Practice (GCP) - What is the cost of GCP-related activities? A survey within the Swedish Association of the Pharmaceutical Industry (LIF)'s members

Quality Assurance Journal

Volumn 12, Issue 1, 2009, Pages 3-7

  Funning, Sandra ^a   Grahnén, Anders ^a   Eriksson, Karin ^b   Kettis Linblad, Åsa ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b The Swedish Association of the Pharmaceutical Industry   (Sweden)

Author keywords

Cost; GCP; SDV; Sweden

Indexed keywords

DRUG;

ARTICLE; BUDGET; CLINICAL TRIAL; DRUG INDUSTRY; FINANCIAL MANAGEMENT; GOOD CLINICAL PRACTICE; HUMAN; INFORMATION PROCESSING; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; PRIORITY JOURNAL; PROCESS MONITORING; QUALITY CONTROL; QUESTIONNAIRE; RELIABILITY; SWEDEN; UNSPECIFIED SIDE EFFECT;

EID: 67449147167     PISSN: 10878378     EISSN: 10991786     Source Type: Journal    
DOI: 10.1002/qaj.433     Document Type: Article

References (5)

1. DiMasi JA, Grabowski HG. The cost of Biopharmaceutical R&D: Is biotech different? Manage Decis Econ 2007; 28: 469-479.
2. Lörstad M. Data quality of the clinical trial process-costly regulatory compliance at the expense of scientific proficiency. Qual Assur J 2004; 8: 177-182.
3. Grahnén AE, Karlsson K, Bragazzi F. Impact of transcription errors on the outcome of a clinical trial. Clin Pharm Ther Suppl 2007; 81: PI-29.
4. Grimes DA, Hubacher D, Nanda K, Schulz KF, Moher D, Altman DG. The good clinical practice guideline: a bronze standard for clinical research. Lancet 2005; 366: 172-174.
5. Personal Communication: Mr Gunnar Danielsson, MPA, Uppsala, March 6, 2007.